Cargando…
DDRE-34. TARGETING RESISTANCE IN MEDULLOBLASTOMA
Medulloblastoma is the most commonly diagnosed pediatric brain tumor. Although therapeutic advances have improved survival from this cancer, they result in devastating sequelae and, additionally, have proven inadequate in metastatic disease and recurrence where survival remains <5%. Effective the...
Autores principales: | Chang, Simone, Meiman, Evan, Telang, Sucheta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992245/ http://dx.doi.org/10.1093/noajnl/vdab024.056 |
Ejemplares similares
-
DDRE-02. SMOOTHENED-ACTIVATING LIPIDS DRIVE RESISTANCE TO CDK4/6 INHIBITION IN HEDGEHOG-ASSOCIATED MEDULLOBLASTOMA
por: Daggubati, Vikas, et al.
Publicado: (2021) -
DDRE-24. TARGETING PURINE METABOLISM TO OVERCOME GLIOBLASTOMA THERAPY RESISTANCE
por: Zhou, Weihua, et al.
Publicado: (2021) -
DDRE-09. THERAPEUTIC TARGETING OF PURINE METABOLISM IN DIPG
por: Mersich, Ian, et al.
Publicado: (2021) -
DDRE-22. TARGETING SERINE SYNTHESIS IN BRAIN METASTASIS
por: Ngo, Bryan, et al.
Publicado: (2021) -
DDRE-11. TARGETING FATTY ACID BIOSYNTHESIS IN GLIOBLASTOMA
por: Eyme, Katharina M, et al.
Publicado: (2021)